Sydney, Australia, November 19, 2026
Actinogen Medical Limited has announced topline results from its pivotal Phase 2b/3 XanaMIA clinical trial evaluating its investigational oral therapy Xanamem® (emestedastat) in people with mild to moderate Alzheimer’s disease. The 36-week, randomised, double-blind, placebo-controlled study enrolled 247 participants with elevated levels of the blood biomarker pTau181 across Australia and the United States. Although Xanamem did not demonstrate a statistically significant benefit over placebo on the trial’s primary endpoint in the overall study population, a prespecified analysis identified encouraging findings among participants older than 75 years. In this subgroup, the treatment was associated with a significantly higher proportion of participants experiencing no disease progression compared with placebo. The company also reported a favourable safety profile over the 36-week treatment period, with no serious adverse events attributed to Xanamem. These findings provide additional information about the investigational medicine’s potential in an older Alzheimer’s population, although further analysis and clinical research will be necessary to establish its effectiveness. Actinogen plans to discuss the results with potential development partners and the U.S. FDA as it considers the next steps for the programme.
XanaMIA Trial Evaluates Xanamem in Alzheimer’s Disease
The XanaMIA study evaluated Xanamem 10 mg administered once daily against placebo over 36 weeks in 247 participants diagnosed with mild to moderate Alzheimer’s disease and elevated plasma pTau181 levels. The primary endpoint measured disease progression using the Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB) at Weeks 12, 24 and 36. This assessment measures changes across cognitive and functional domains, including memory, orientation, judgement and everyday activities. In the overall trial population, Xanamem showed a numerical advantage over placebo at Week 36, with a mean treatment difference of 0.10 CDR-SB points. However, this result was not statistically significant (p=0.65), meaning the study did not establish that Xanamem slowed disease progression across the entire enrolled population. Small, non-significant trends favouring Xanamem were also reported for the key secondary endpoints assessing cognition and activities of daily living. These results are important for interpreting the trial because they show that the overall efficacy objective was not achieved. The findings should therefore not be described as a successful pivotal trial demonstrating significant benefit across all participants.
Older Participants Show Encouraging Disease-Stabilisation Findings
A notable finding emerged from the prespecified analysis of participants above the trial’s median age of 75 years. In this subgroup, 40% of participants receiving Xanamem experienced no disease progression, compared with 22% of those receiving placebo. This difference was statistically significant, with a p-value of 0.02. Actinogen also reported a 0.39-point mean CDR-SB advantage at Week 36 in this subgroup, corresponding to an estimated 30% slowing of disease progression. However, this latter comparison was not statistically significant (p=0.22) and should be interpreted as an encouraging numerical finding rather than confirmed efficacy. The company believes the results may be related to increased expression of the target enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with ageing. Older adults represent a substantial proportion of people living with Alzheimer’s disease and frequently have other medical conditions requiring multiple medications. Actinogen has highlighted the potential relevance of Xanamem’s safety and drug-interaction profile for this population. Nevertheless, subgroup findings from a trial that missed its overall primary endpoint require further investigation and confirmation in additional studies before they can support a definitive treatment claim.
Cortisol-Targeting Mechanism and Safety Profile
Xanamem, also known as emestedastat, is an investigational oral medicine designed to inhibit the enzyme 11β-HSD1, which produces active cortisol in tissues, including the brain. The treatment aims to reduce excessive local cortisol production without blocking normal cortisol production by the adrenal glands. The scientific rationale is based on evidence linking chronically elevated cortisol with processes associated with Alzheimer’s disease progression and neuronal damage. By reducing cortisol production in relevant brain regions, the medicine is being investigated for its potential to influence disease-related changes. In the XanaMIA trial, the previously reported favourable safety profile was maintained during the longer 36-week treatment period. The company reported that no serious adverse events were attributed to Xanamem. More than 500 people have reportedly received the medicine across its clinical development programme. The trial also included an open-label extension phase, with initial observations from the first 29 participants reaching 24 weeks of active treatment showing no mean progression on the CDR-SB measure. Actinogen plans to report another extension-phase data update in the first quarter of 2027, when approximately 100 participants are expected to have completed at least 24 weeks of treatment. Xanamem remains investigational and is not approved by the FDA or any other global regulatory authority. Further clinical evidence will be required to determine whether the older-patient findings can be reproduced and translated into a meaningful treatment benefit.
Source: Actinogen Medical press release



